Key Highlights
- ARK offloaded 50,312 shares of Rocket Lab valued at approximately $4 million via ARKQ ETF on April 27
- The aerospace stock sale marks ARK’s second divestment following last Friday’s 113,000+ share reduction
- The firm accumulated 263,848 shares of Intellia Therapeutics totaling roughly $3.6 million through ARKK and ARKG funds
- ARK divested 13,806 Iridium Communications shares valued at approximately $538,000
- Rocket Lab shares climbed 3.28% to close at $82.29 on Monday despite ARK’s divestment
Cathie Wood’s investment firm ARK Invest executed multiple strategic trades on Monday, April 27, 2026, as revealed in the company’s latest daily transaction reports.
The most significant transaction involved divesting 50,312 shares of Rocket Lab through the ARKQ exchange-traded fund, representing approximately $4.01 million in value. This divestment occurred merely days following ARK’s sale of more than 113,000 shares of the aerospace manufacturer the preceding Friday.
The consecutive sales within a brief timeframe indicate ARK is strategically reducing its exposure to the space technology firm.
The notable aspect of these transactions is that Rocket Lab’s stock experienced a 3.28% gain on Monday, finishing the session at $82.29. Rather than selling during a decline, ARK capitalized on the stock’s upward momentum.
The investment firm seems to be locking in gains before Rocket Lab releases its first quarter 2026 financial results, set for May 7, 2026.
Financial analysts on Wall Street anticipate Rocket Lab will post quarterly revenues of $189.65 million, representing a 55% increase compared to the prior year period. Analysts also forecast a loss of $0.07 per share, showing progress from the $0.12 per share loss recorded during the corresponding quarter in 2025.
ARK Increases Position in Gene-Editing Biotech
While reducing its Rocket Lab holdings, ARK simultaneously accumulated shares of Intellia Therapeutics. The investment firm acquired 263,848 shares distributed between its ARKK and ARKG exchange-traded funds, totaling approximately $3.6 million.
Intellia specializes in gene-editing technology, and its shares declined 4.33% during Monday’s trading session. ARK capitalized on this price weakness as an entry point.
This purchasing behavior aligns with ARK’s established strategy of increasing holdings during temporary declines in companies it considers promising long-term investments.
Additionally, ARK divested 13,806 shares of Iridium Communications via its ARKX ETF, totaling roughly $538,000. This transaction extends a developing pattern — ARK previously sold 33,315 Iridium shares last Friday and 81,422 shares during the Monday prior.
Wall Street Perspective on Rocket Lab
Notwithstanding ARK’s ongoing divestment, certain Wall Street analysts maintain optimistic outlooks on Rocket Lab.
Stifel analyst Erik Rasmussen elevated his price objective for the stock from $90 to $105 while maintaining a Buy recommendation. His upgraded outlook stems from consistent revenue expansion, a robust order backlog, and the anticipated debut of the Neutron rocket system later in 2026.
Per TipRanks data, Rocket Lab maintains a Moderate Buy consensus among analysts, supported by nine Buy recommendations and four Hold ratings issued during the most recent three-month period.
The consensus price target among analysts stands at $89.00, suggesting potential upside of approximately 8% from present trading levels.
ARK’s subsequent daily trading disclosure will reveal whether the firm continued decreasing its Rocket Lab stake on Tuesday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
